ENTA Stock — Enanta Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

Our active development programs in virology are focused on respiratory syncytial virus, or RSV, the most common cause of bronchiolitis and pneumonia and a leading cause of U.S. hospitalization in young children and a significant cause of respiratory illness in older adults.

Source: 10-K FY2025 via SEC EDGAR

Share price

$11.00

Market cap

$320.4M

Cash

$211.5M

Enterprise value

$108.9M

Balance sheet

Cash	$211.5M
Debt	$0.0M
Net cash	$211.5M
Enterprise value	$108.9M
Basic shares	29.1M shares
Fully diluted shares	36.4M shares
Fully diluted market cap	$400.6M
Cash per share	$7.26
Quarterly burn	$10.0M
Cash runway	21.2 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

29.1M

Pre-funded warrants

0.0M

Options

6.7M

RSUs

0.6M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

36.4M

Cap table as of 2026-06-30.

Price history

Loading ENTA daily closes…

Loading price history…

Next catalyst

EPS-3903 · Est. Nov 7, 2026 · half midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now half midpoint	EPS-3903	Not disclosed	Not disclosed	2H 2026
Dec 13, 2026 - Jan 24, 2027 in 5 wks	EDP-978	Phase 1	Chronic Inducible Urticaria; Chronic Spontaneous Urticaria	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
Jan 12 - Feb 23 in 9 wks	zelicapavir	Phase 2	RSV Infection; RSV; Respiratory Syncytial Virus (RSV)	2027 Est. Jul 2, 2027 · guidance midpoint
GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint	zelicapavir RESOLVE registrational Phase 2b/3 in high-risk adults with RSV	Phase 2b	high-risk adults with RSV	2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

zelicapavir

Phase 2 · Active Modality: small molecule (oral, once-daily)

Aliases EDP-938

Target RSV N-protein

Indications

Respiratory syncytial virus (RSV) in high-risk adults (Phase 2)
RSV in pediatric patients (28 days to 36 months) (Phase 2)

Catalysts

— Q4 2026
— 2027
— 2027

Status note Lead program. FDA Fast Track for RSV. Positive Phase 2b topline in high-risk adults (Sep 2025) and Phase 2 in pediatrics (Dec 2024). RESOLVE and LOTUS (first participant dosed Q3 2026) are the named next trials; company is exploring business development for RSV programs.

EDP-323

Phase 2 · Active Modality: small molecule (oral, once-daily)

Target RSV L-protein

Indications

Respiratory syncytial virus (RSV) (Phase 2)

Status note FDA Fast Track for RSV. Positive Phase 2a challenge study topline (Sep 2024), including post-exposure prophylaxis signal. No next trial details stated; development focus is on zelicapavir.

EDP-978

Phase 1 · Active Modality: small molecule (oral, once-daily)

Target KIT

Indications

Chronic spontaneous urticaria (CSU) (Phase 1)

Catalysts

— Q4 2026

Status note Clinical immunology candidate targeting mast cell depletion; Phase 1 in healthy volunteers dosed first participant April 2026; potential expansion to other mast cell-associated indications.

EPS-3903

Preclinical · Active Modality: small molecule (oral)

Target STAT6

Indications

Atopic dermatitis (AD) (Preclinical)

Catalysts

— 2H 2026

Status note Preclinical lead candidate in STAT6 inhibitor program; initial proof-of-concept planned in AD, then other indications where IL-4/IL-13 pathway blockade applies. IND-enabling/scale-up ongoing.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	zelicapavir
Lead indication	RSV Infection
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07482657	Phase 2	Recruiting	Sponsor	ENTA	—	RSV Infection; RSV; Respiratory Syncytial Virus (RSV)	2027 Est. Jul 2, 2027 · guidance midpoint
NCT07540910	Phase 1	Recruiting	Sponsor	ENTA	—	Chronic Inducible Urticaria; Chronic Spontaneous Urticaria	Q4 2026 Est. Nov 15, 2026 · quarter midpoint

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Enanta Pharmaceuticals, Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	1,344,510	+1,293,153	0.92%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ENTA — Enanta Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ENTA — Enanta Pharmaceuticals Inc.